Company Overview
Heqet Therapeutics is a pre-clinical stage biotech company focused on the development of non-coding RNA-based therapies to treat cardiovascular diseases, with a specific focus on acute myocardial infarction. The company stems from the groundbreaking research carried out by Prof. Mauro Giacca, currently Professor of Cardiovascular Sciences and Head of the School of Cardiovascular and Metabolic Medicine & Sciences, King’s College London.
Millions of patients in the world suffer a myocardial infarction every year, with ischemic heart disease still being one of the leading causes of death worldwide. Heqet Therapeutics is advancing its pipeline of first-in-class compounds for cardiac regeneration to address this large unmet clinical need.
Our Team
Mauro Giacca – Scientific Founder and BoD Member
Mauro Giacca, MD PhD, is Professor of Cardiovascular Sciences and Head of the School of Cardiovascular and Metabolic Medicine & Sciences, King’s College London. Until 2019, he has served as the Director-General of the International Centre for Genetic Engineering and Biotechnology (ICGEB), an organization in the United Nations system based in Italy. From 2005, he is a Full Professor of Molecular Biology at the University of Trieste. From 2000-04, he has been Professor of Molecular Biology and Director of the Molecular Biology Laboratory at Scuola Normale Superiore in Pisa, one of the leading academic institutions in Italy. He is the President of the International Society for Heart Research (ISHR) European Section and serves on the scientific boards of numerous academic institutions and biotech companies internationally. Since 2021, he is an elected Fellow of the Academy of Medical Sciences of the United Kingdom. He received his Degree in Medicine from the University of Trieste, Italy in 1984 and his PhD in Microbiology and Virology from the University of Genoa, Italy in 1989.
